NIVOLUMAB IN THE TREATMENT OF REFRACTORY RECURRENT AND METАSTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. THE RESULTS OF A PHASE III CLINICAL TRIAL (CHECKMATE 141)

Head and neck squamous cell carcinoma (HNSCC) is one of the most common causes of cancer death. More than 50% of patients with locally advanced tumors relapse. Median survival of patients with recurrent HNSCC developed within 6 month after treatment completion does not exceed 6 months. One of the most important biological processes involved in the disease progression is tumor escape from immune response associated with the expression of programmed death receptor-1 (PD-1), which inhibits the anti-tumor immune response. The emergence of cancer immunotherapy made revolutionary changes in cancer treatment. The article presents the results of a randomized clinical trial of nivolumab for the treatment of recurrent and metastatic HNSCC (CheckMate) 141. Nivolumab improved overall survival of patients with progressive HNSCC refractory to standard therapy. It increased the frequency and median duration of objective anti-tumor responses as well as median overall survival regardless of the PD-L1 expression levels and association of cancer with human papillomavirus. Moreover, the majority of patients receiving nivolumab reported no reduction in their quality of life, which enables long-term therapy in such patients.  The results of the CheckMate-141 study appear very promising and require further investigation of nivolumab in patients with primary HNSCC, especially in combination with standard treatment methods (first-line chemotherapy, radiotherapy) or other immunotherapeutic agents.

head and neck tumors, squamous cell carcinoma, programmed death receptor-1, immunotherapy, targeted drug, nivolumab, cetuximab, CheckMate 141

1. Pignon J.P., le Maître A., Maillard E., Bourhis J.; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4–14. DOI: 10.1016/j.radonc.2009.04.014. PMID: 19446902.

2. Bernier J., Domenge C., Ozsahin M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350(19):1945–52. DOI: 10.1056/NEJMoa032641. PMID: 15128894.

3. Cooper J.S., Pajak T.F., Forastiere A.A. et al. Postoperative concurrent radiotherapy and chemotherapy for highrisk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937–44. DOI: 10.1056/NEJMoa032646. PMID: 15128893.

4. Saloura V., Cohen E.E., Licitra L. et al. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2014;73:1227–39. DOI: 10.1007/s00280-014-2459-z. PMID: 24714973.

5. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450–61. DOI: 10.1016/j.ccell.2015.03.001. PMID: 25858804.

6. Li J., Jie H.B., Lei Y. et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015;75:508–18. DOI: 10.1158/00085472.CAN-14-1215. PMID: 25480946.

7. Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128–38. DOI: 10.1158/0008-5472.CAN-12-2606. PMID: 23135914.

8. Concha-Benavente F., Srivastava R.M., Trivedi S. et al. Identification of the cellintrinsic and -extrinsic pathways downstream of EGFR and IFNγ that inducePD-L1 expression in head and neck cancer. Cancer Res 2016;76:1031–43. DOI: 10.1158/0008-5472.CAN-15-2001. PMID: 26676749.

9. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136–51. DOI: 10.1200/jco.2004.10.041.

10. Muenst S., Läubli H., Soysal S.D. et al. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med 2016; 279(6):541–62. DOI: 10.1111/joim.12470. PMID: 26748421.

11. Gillison M.L. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 2009;21:439–44. DOI: 10.1097/CCO.0b013e32832f3e1b.

12. Fuereder T. Immunotherapy for head and neck squamous cell carcinoma. memo (2016) 9:66–69. DOI 10.1007/s12254016-0270-8.

13. Ferris R.L. Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015;33:3293–304. DOI: 10.1200/jco.2015.61.1509.

14. Kuss I., Hathaway B., Ferris R.L., Gooding W., Whiteside T.L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:3755–62. DOI: 10.1158/1078–0432.ccr-04-0054.

15. Nguyen N., Bellile E., Thomas D. et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. HeadNeck 2016;38(7):1074–84. DOI: 10.1002/ hed.24406. PMID: 26879675.

16. Lalami Y., Awada A. Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treat Rev 2016;43:113–23. DOI: 10.1016/j.ctrv.2016.01.001.

17. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. DOI: 10.1038/nature10673. PMID: 26827699.

18. Zandberg D.P., Strome S.E. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014;50:627–32. DOI: 10.1016/j.oraloncology.2014.04.003. PMID: 24819861.

19. Parikh F., Duluc D., Imai N. et al. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPVrelated oropharyn-gealcancer. Cancer Res 2014; 74(24):7205–16. DOI: 10.1158/0008-5472.can-14-1913.

20. Swanson M.S., Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer – Review of current data. Oral Oncology 2015; 51:12–15. DOI: 10.1016/j.oraloncology.2014.10.010. PMID: 25459157.

21. Alexandrov L.B., Nik-Zainal S., Wedge D.C. et al. Signatures of mutational processes in human cancer. Nature 2013;500:415–21. DOI: 10.1038.nature12477. PMID: 23945592.

22. Ferris R.L., Blumenschein G.Jr, Fayette J. et al. Nivolumab for Recurrent SquamousCell Carcinoma of the Head and Neck. N Engl J Med 2016;375(19):1856–67. DOI: 10.1056/NEJMoa1602252. PMID: 27718784.

23. Haddad R. et al. Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the Phase 3 Checkmate 141 Study. Poster presented at the American Association for Cancer Research Annual Meeting; April 1–5, 2017; Washington, DC, USA.

24. Gillison M.L. et al. Presented at ASCO 2017, abstract 6019.

25. Srivastava R.M., Lee S.C., Andrade Filho P.A. et al. Cetuximab-activated natural killer and dendabstractritic cells collaborate to trigger tumor antigenspecific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013;19:1858–72.

26. Concha-Benavente F., Srivastava R.M., Trivedi S. et al. Identification of the CellIntrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 2016;76(5):1031–43.

27. Ferris R.L. et al. Presented at ASCO 2017, abstract 6020. 28. Concha-Benavente F. et al. Presented at ASCO 2017, abstract 6050.